Harvard Bioscience Announces Third Quarter 2022 Financial Results

Rhea-AI Summary

Harvard Bioscience (Nasdaq: HBIO) reported Q3 2022 revenues of $26.9 million, a 9% decline year-over-year, driven by a 17% drop in pre-clinical product sales. Gross margin fell due to lower revenues and increased labor/material costs. The company anticipates Q4 revenues to reach approximately $30 million, with improved operating margins between 14%-15%. Key product launches include the Ultrospec 7500 and continuous glucose monitoring devices. Cost optimization efforts are expected to yield $4 million in annual gross margin improvements.

Positive

• Q4 revenue expected around $30 million.
• Adjusted operating margin projected between 14% and 15%.
• Introduction of three new products expected to drive growth.

Negative

• Revenue decreased by 9% year-over-year.
• Operating loss of $3.8 million compared to a profit of $0.5 million in Q3 2021.
• Gross margin down due to increased costs and lower revenue.

 “Fighting through challenging times while building the company and new technologies for the future.”

HOLLISTON, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the third quarter ended September 30, 2022.

Jim Green, Chairman and CEO, said, "Impacted by a challenging summer, our third quarter revenues were $26.9 million, down 9% from the same quarter prior year. Growth of 6% in our cellular/molecular product revenues were more than offset by a 17% reduction in sales of our higher margin pre-clinical products and a negative currency impact of approximately $1.0 million. Gross margin was down on lower revenue as well as higher costs of labor and materials, in addition to inventory charges related to the discontinuation of certain non-strategic products as a result of our previously communicated portfolio optimization. Operating margin was down from last year mainly on lower sales and lower gross margin.”

Green continued, “In spite of headwinds in the quarter, we expect sequential revenue growth and an improved product mix in Q4 resulting in our gross margins returning to first half levels. Q4 revenue is expected to be in the $30 million dollar range, with adjusted operating margin in the range of 14% to 15%.

We’re very pleased to see our continued investment in research and development deliver three new product introductions. First, our new Ultrospec 7500 is a premium spectrophotometer well known in the academic laboratories now also targeted to the pharma/CRO space. Second is our exclusive continuous glucose monitoring telemetry implants driving new demand in academic, pharma, and government labs focused on ever increasing diabetes.  Lastly, we’re excited to see a large Q4 order for our BTX electroporation system using our unique Flat Pack Reaction Chamber to a top pharma company for use in bioproduction. Furthering these initial inroads, we see an emerging value proposition for our BTX system, which is often used in pharmaceutical research and development to create the initial strains of a therapeutic, to be used more broadly in production.”

Green concluded, “Looking to the future, we expect to complete our portfolio optimization and related cost actions in Q4, with anticipated annual improvements of approximately $4.0 million in gross margin and operating expense reductions of approximately $1.5 million as we enter 2023. This leaning activity, combined with improved pricing and exciting new product introductions, is expected to drive new growth and make 2023 the year the company becomes the profitable growth-oriented platform we envisioned.”

Quarterly Financial Results Summary		Q3'22				Q3'21
Revenues		$	26.9	million		$	29.7	million
Operating (Loss) Income (GAAP)		$	(3.8)	million		$	0.5	million
Adjusted Operating Income		$	0.7	million		$	3.9	million
Operating Margin (GAAP)		(14.0)		%		1.8		%
Adjusted Operating Margin		2.6		%		13.3		%
Diluted Loss Per Share (GAAP)		$	(0.08)			$	(0.00)
Diluted Adjusted (Loss) Earnings Per Share		$	(0.01)			$	0.06
Net Debt*		$	45.0	million		$	40.9	million
* Debt outstanding less cash and cash equivalents

For more details on performance for the three and nine months ended September 30, 2022, a slide presentation that will be referenced during the webcast referenced below will be posted to our Investor Relations website shortly before the webcast begins.

Please refer to the exhibits below for a reconciliation of certain non-GAAP to GAAP financial measures, including gross margin, operating income, net income and loss, diluted earnings per share and adjusted EBITDA. Please see “Use of Non-GAAP Financial Information” for additional information regarding our use of such adjusted financial information.

Webcast and Conference Call Details

Harvard Bioscience will be hosting a conference call and webcast today at 4:30 p.m. Eastern Time. 

Covering Analysts who want to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. 

Participants who want to join the audio-only webcast should go to our events and presentations on the investor website here. 

Use of Non-GAAP Financial Information

In this press release, we have included non-GAAP financial information including adjusted operating income, adjusted operating margin, and adjusted earnings per share. We believe that this non-GAAP financial information provides investors with an enhanced understanding of the underlying operations of the business. For the periods presented, these non-GAAP financial measures have excluded certain expenses and income resulting from items that we do not believe are representative of the underlying operations of the business, such as amortization of intangibles related to acquisitions, costs related to acquisition, disposition and integration initiatives, impairment charges, severance, restructuring and other business transformation expenses, and stock-based compensation expense, and litigation settlement expenses. They also exclude the tax impact of the reconciling items. Management believes that this non-GAAP financial information is important in comparing current results with prior period results and is useful to investors and financial analysts in assessing the Company’s operating performance. Any non-GAAP financial statement information included herein is accompanied by a reconciliation to the nearest corresponding GAAP measure which are included as exhibits below in this press release.

The non-GAAP financial information provided in this press release should be considered in addition to, not as a substitute for, the financial information provided and presented in accordance with GAAP and may be different than other companies’ non-GAAP financial information.

About Harvard Bioscience

Harvard Bioscience is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Our customers range from renowned academic institutions and government laboratories, to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.

For more information, please visit our website at www.harvardbioscience.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. You can identify these statements by our use of such words as "will," "guidance," "objectives," "optimistic," "potential," "future," "expects," "plans," "estimates," "continue," "drive," "strategy," "potential," "potentially," "growth," "long-term," "projects," "projected," "intends," "believes," "goals," "sees," "seek," "develop" "possible" "new," "emerging," "opportunity," "pursue" and similar expressions that do not relate to historical matters. Forward-looking statements in this press release or that may be made during our conference call may include, but are not limited to, statements or inferences about the Company's or management's beliefs or expectations, the Company's anticipated future revenues and earnings, the strength of the Company's market position and business model, industry outlook, the impact of the COVID-19 pandemic and related supply chain disruptions on the Company’s business, the Company's business strategy, the positioning of the Company for growth, the market demand and opportunity for the Company's current products, or products it is developing or intends to develop, and the Company's plans, objectives and intentions that are not historical facts. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Investors should note that many factors, as more fully described under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021, and in our other filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein may cause the Company's actual results to differ materially from those in the forward-looking statements. The forward-looking statements in this press release are qualified by these risk factors. The Company's results may also be affected by factors of which the Company is not currently aware. The Company may not update these forward-looking statements, even though its situation may change in the future, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.

Investor Inquiries:

Michael Rossi
Chief Financial Officer
(508)893-8999
mrossi@harvardbioscience.com

HARVARD BIOSCIENCE, INC.
Consolidated Statements of Operations
(unaudited, in thousands, except per share data)
		Three Months Ended								Nine Months Ended
		September 30, 2022				September 30, 2021				September 30, 2022				September 30, 2021
	Revenues	$	26,922			$	29,663			$	84,908			$	85,849
	Cost of revenues		14,750				13,355				39,922				37,757
	Gross profit		12,172				16,308				44,986				48,092
	Operating expenses:
	Sales and marketing expenses		5,819				6,183				19,093				17,299
	General and administrative expenses		6,324				5,458				18,630				18,190
	Research and development expenses		2,763				2,660				9,480				7,848
	Amortization of intangible assets		1,572				1,459				4,492				4,388
	Settlement of litigation, net		(544	)			-				(233	)			-
	Total operating expenses		15,934				15,760				51,462				47,725
	Operating (loss) income		(3,762	)			548				(6,476	)			367
	Other expense:
	Interest expense		(749	)			(373	)			(1,648	)			(1,161	)
	Other expense, net		(179	)			(130	)			(163	)			(477	)
	Total other expense		(928	)			(503	)			(1,811	)			(1,638	)
	(Loss) income before income taxes		(4,690	)			45				(8,287	)			(1,271	)
	Income tax (benefit) expense		(1,285	)			215				(437	)			(22	)
	Net loss	$	(3,405	)		$	(170	)		$	(7,850	)		$	(1,249	)
	Loss per common share:
	Basic and diluted	$	(0.08	)		$	(0.00	)		$	(0.19	)		$	(0.03	)
	Weighted-average common shares:
	Basic and diluted		41,637				40,754				41,353				40,202

HARVARD BIOSCIENCE, INC.
Condensed Consolidated Balance Sheets
(unaudited, in thousands)
			September 30, 2022			December 31, 2021
	Assets
	Cash and cash equivalents	$	5,144		$	7,821
	Accounts receivables		15,023			21,834
	Inventories		26,116			27,587
	Other current assets		5,535			4,341
	Total current assets		51,818			61,583
	Property, plant and equipment		3,555			3,415
	Goodwill and other intangibles		77,315			85,074
	Other long-term assets		14,325			12,272
	Total assets	$	147,013		$	162,344
	Liabilities and Stockholders' Equity
	Current portion, long-term debt	$	2,720		$	3,235
	Other current liabilities		18,640			22,081
	Total current liabilities		21,360			25,316
	Long-term debt, net		46,534			45,095
	Other long-term liabilities		7,140			8,532
	Stockholders’ equity		71,979			83,401
	Total liabilities and stockholders’ equity	$	147,013		$	162,344

HARVARD BIOSCIENCE, INC.
Condensed Consolidated Statements of Cash Flows
(unaudited, in thousands)
		Nine Months Ended
		September 30, 2022				September 30, 2021
	Cash flows from operating activities:
	Net loss	$	(7,850	)		$	(1,249	)
	Adjustments to operating cash flows		5,165				8,547
	Changes in operating assets and liabilities		1,158				(6,153	)
	Net cash (used in) provided by operating activities		(1,527	)			1,145
	Cash flows from investing activities:
	Additions to property, plant and equipment		(1,355	)			(837	)
	Additions to intangible assets		-				(150	)
	Net cash used in investing activities		(1,355	)			(987	)
	Cash flows from financing activities:
	Borrowing from revolving line of credit		7,800				2,500
	Repayment of revolving line of credit		(4,650	)			(4,000	)
	Repayment of term debt		(2,436	)			(1,500	)
	Payments of debt issuance costs		-				(102	)
	Proceeds from exercise of stock options and stock purchases		346				2,909
	Taxes related to net share settlement of equity awards		(1,167	)			(2,653	)
	Net cash used in financing activities		(107	)			(2,846	)
	Effect of exchange rate changes on cash		312				(81	)
	Decrease in cash and cash equivalents		(2,677	)			(2,769	)
	Cash and cash equivalents at the beginning of period		7,821				8,317
	Cash and cash equivalents at the end of period	$	5,144			$	5,548

HARVARD BIOSCIENCE, INC.
Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)
Three Months Ended September 30, 2022
(in thousands, except per share data)
														Settlement,
														Restructuring,
						Stock-Based				Acquired Assets				Transformation				Income
	Statement of Operations	GAAP				Compensation				Amortization				& Other				Taxes				ADJUSTED
	Revenues	$	26,922			-				-				-				-				$	26,922
	Cost of revenues	14,750				-				(7		)		(1,441		)		-				13,302
	Gross profit	12,172				-				7				1,441				-				13,620
	Gross Margin	45.2		%																		50.6		%
	Operating expenses:
	Sales and marketing expenses	5,819				(147		)		(1		)		120				-				5,791
	General and administrative expenses	6,324				(919		)		(8		)		(942		)		-				4,455
	Research and development expenses	2,763				(73		)		(8		)		(10		)		-				2,672
	Amortization of intangible assets	1,572				-				(1,572		)		-				-				-
	Settlement of litigation, net	(544		)		-				-				544				-				-
	Total operating expenses	15,934				(1,139		)		(1,589		)		(288		)		-				12,918
	Operating Expenses - % of Revenues	59.2		%																		48.0		%
	Operating (loss) income	(3,762		)		1,139				1,596				1,729				-				702
	Operating Margin	-14.0		%																		2.6		%
	Other expense:
	Interest expense	(749		)		-				-				-				-				(749		)
	Other expense, net	(179		)		-				-				(80		)		-				(259		)
	Total other expense	(928		)		-				-				(80		)		-				(1,008		)
	Loss before income taxes	(4,690		)		1,139				1,596				1,649				-				(306		)
	Income tax benefit	(1,285		)		-				-				-				1,244				(41		)
	Net loss	$	(3,405	)		$	1,139			$	1,596			$	1,649			$	(1,244	)		$	(265	)
	Loss per share	$	(0.08	)																		$	(0.01	)
	Diluted weighted average common shares	41,637																				41,637

HARVARD BIOSCIENCE, INC.
Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)
Three Months Ended September 30, 2021
(in thousands, except per share data)
						Stock-Based				Acquired Assets				Restructuring,				Income
	Statement of Operations	GAAP				Compensation				Amortization				Transformation				Taxes				ADJUSTED
	Revenues	$	29,663			-				-				-				-				$	29,663
	Cost of revenues	13,355				(32		)		(15		)		(94		)		-				13,214
	Gross profit	16,308				32				15				94				-				16,449
	Gross Margin	55.0		%																		55.5		%
	Operating expenses:
	Sales and marketing expenses	6,183				(149		)		(2		)		(261		)		-				5,771
	General and administrative expenses	5,458				(790		)		(16		)		(426		)		-				4,226
	Research and development expenses	2,660				(33		)		(10		)		(113		)		-				2,504
	Amortization of intangible assets	1,459				-				(1,459		)		-				-				-
	Total operating expenses	15,760				(972		)		(1,487		)		(800		)		-				12,501
	Operating Expenses - % of Revenues	53.1		%																		42.1		%
	Operating income	548				1,004				1,502				894				-				3,948
	Operating Margin	1.8		%																		13.3		%
	Other expense:
	Interest expense	(373		)		-				-				-				-				(373		)
	Other expense, net	(130		)		-				-				-				-				(130		)
	Total other expense	(503		)		-				-				-				-				(503		)
	Income before income taxes	45				1,004				1,502				894				-				3,445
	Income tax expense	215				-				-				-				580				795
	Net (loss) income	$	(170	)		$	1,004			$	1,502			$	894			$	(580	)		$	2,650
	(Loss) income per share	$	(0.00	)																		$	0.06
	Diluted weighted average common shares	40,754																				43,500

HARVARD BIOSCIENCE, INC.
Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)
Nine Months Ended September 30, 2022
(in thousands, except per share data)
														Settlement,
														Restructuring,
						Stock-Based				Acquired Assets				Transformation				Income
	Statement of Operations	GAAP				Compensation				Amortization				& Other				Taxes				ADJUSTED
	Revenues	$	84,908			-				-				-				-				$	84,908
	Cost of revenues	39,922				(88		)		(27		)		(1,598		)		-				38,209
	Gross profit	44,986				88				27				1,598				-				46,699
	Gross Margin	53.0		%																		55.0		%
	Operating expenses:
	Sales and marketing expenses	19,093				(493		)		(4		)		(250		)		-				18,346
	General and administrative expenses	18,630				(2,633		)		(38		)		(2,861		)		-				13,098
	Research and development expenses	9,480				(187		)		(27		)		(137		)		-				9,129
	Amortization of intangible assets	4,492				-				(4,492		)		-				-				-
	Settlement of litigation, net	(233		)		-				-				233				-				-
	Total operating expenses	51,462				(3,313		)		(4,561		)		(3,015		)		-				40,573
	Operating Expenses - % of Revenues	60.6		%																		47.8		%
	Operating (loss) income	(6,476		)		3,401				4,588				4,613				-				6,126
	Operating Margin	-7.6		%																		7.2		%
	Other expense:
	Interest expense	(1,648		)		-				-				-				-				(1,648		)
	Other expense, net	(163		)		-				-				(80		)		-				(243		)
	Total other expense	(1,811		)		-				-				(80		)		-				(1,891		)
	(Loss) income before income taxes	(8,287		)		3,401				4,588				4,533				-				4,235
	Income tax (benefit) expense	(437		)		-				-				-				1,409				972
	Net (loss) income	$	(7,850	)		$	3,401			$	4,588			$	4,533			$	(1,409	)		$	3,263
	(Loss) income per share	$	(0.19	)																		$	0.08
	Diluted weighted average common shares	41,353																				42,665

HARVARD BIOSCIENCE, INC.
Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)
Nine Months Ended September 30, 2021
(in thousands, except per share data)
						Stock-Based				Acquired Assets				Restructuring,				Income
	Statement of Operations	GAAP				Compensation				Amortization				Transformation				Taxes				ADJUSTED
	Revenues	$	85,849			-				-				-				-				$	85,849
	Cost of revenues	37,757				(83		)		(51		)		(247		)		-				37,376
	Gross profit	48,092				83				51				247				-				48,473
	Gross Margin	56.0		%																		56.5		%
	Operating expenses:
	Sales and marketing expenses	17,299				(373		)		(6		)		(375		)		-				16,545
	General and administrative expenses	18,190				(2,593		)		(49		)		(2,380		)		-				13,168
	Research and development expenses	7,848				(87		)		(32		)		(408		)		-				7,321
	Amortization of intangible assets	4,388				-				(4,388		)		-				-				-
	Total operating expenses	47,725				(3,053		)		(4,475		)		(3,163		)		-				37,034
	Operating Expenses - % of Revenues	55.6		%																		43.1		%
	Operating income	367				3,136				4,526				3,410				-				11,439
	Operating Margin	0.4		%																		13.3		%
	Other expense:
	Interest expense	(1,161		)		-				-				-				-				(1,161		)
	Other expense, net	(477		)		-				-				-				-				(477		)
	Total other expense	(1,638		)		-				-				-				-				(1,638		)
	(Loss) income before income taxes	(1,271		)		3,136				4,526				3,410				-				9,801
	Income tax (benefit) expense	(22		)		-				-				-				2,365				2,343
	Net (loss) income	$	(1,249	)		$	3,136			$	4,526			$	3,410			$	(2,365	)		$	7,458
	(Loss) income per share	$	(0.03	)																		$	0.17
	Diluted weighted average common shares	40,202																				43,113

HARVARD BIOSCIENCE, INC.
Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)
(in thousands)
		Three Months Ended							Nine Months Ended
		September 30, 2022				September 30, 2021			September 30, 2022				September 30, 2021
	Operating income	$	(3,762	)		$	548		$	(6,476	)		$	367
	Stock-based compensation expense		1,139				1,004			3,401				3,136
	Acquired asset amortization		1,596				1,502			4,588				4,526
	Settlements, restructuring and transformation costs		1,729				894			4,613				3,410
	Adjusted operating income		702				3,948			6,126				11,439
	Depreciation expense		364				420			1,122				1,311
	Adjusted EBITDA	$	1,066			$	4,368		$	7,248			$	12,750

 

FAQ

What were the Q3 2022 financial results for Harvard Bioscience (HBIO)?

Harvard Bioscience reported Q3 2022 revenues of $26.9 million, down 9% from the previous year, with an operating loss of $3.8 million.

What is the forecast for Q4 2022 revenue for HBIO?

The company expects Q4 2022 revenue to be in the range of $30 million.

What are the new products launched by Harvard Bioscience?

New products include the Ultrospec 7500 spectrophotometer and continuous glucose monitoring telemetry implants.

What improvements does Harvard Bioscience expect in 2023?

The company anticipates annual improvements of approximately $4 million in gross margin and $1.5 million in operating expense reductions in 2023.

How did Harvard Bioscience's operating margin change in Q3 2022?

The operating margin was negative 14.0% for Q3 2022, down from a positive margin of 1.8% in Q3 2021.